BIOMUNEX PHARMACEUTICALS has a total of 39 patent applications. It increased the IP activity by 25.0%. Its first patent ever was published in 2017. It filed its patents most often in Australia, Canada and China. Its main competitors in its focus markets pharmaceuticals and biotechnology are AVACTA LIFE SCIENCES LTD, SHANGHAI EPIMAB BIOTHERAPEUTICS CO LTD and Black Belt Therapeutics Ltd.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 4 | |
#2 | Canada | 4 | |
#3 | China | 4 | |
#4 | EPO (European Patent Office) | 4 | |
#5 | Republic of Korea | 4 | |
#6 | Singapore | 4 | |
#7 | United States | 4 | |
#8 | WIPO (World Intellectual Property Organization) | 4 | |
#9 | Brazil | 2 | |
#10 | Israel | 2 | |
#11 | Mexico | 2 | |
#12 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Zhukovsky Eugene | 33 |
#2 | Leger Olivier | 33 |
#3 | Morse Richard J | 17 |
#4 | Larbouret Christel | 8 |
#5 | Gerard Pierre-Emmanuel | 7 |
#6 | Pelegrin André | 4 |
#7 | Olivier Leger | 4 |
#8 | Eugene Zhukovsky | 4 |
#9 | Pelegrin Andre | 4 |
#10 | Richard J Morse | 1 |
Publication | Filing date | Title |
---|---|---|
AU2018241881A1 | Stable multispecific antibodies | |
US2019330377A1 | A polypeptide linker for preparing multispecific antibodies | |
CN109563166A | The bispecific antibody of targeting EGFR and HER2 | |
US2020010559A1 | Binding molecules to cd38 and pd-l1 |